These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 27935941)

  • 1. Objectives and Design of BLEEDS: A Cohort Study to Identify New Risk Factors and Predictors for Major Bleeding during Treatment with Vitamin K Antagonists.
    van Rein N; Lijfering WM; Bos MH; Herruer MH; Vermaas HW; van der Meer FJ; Reitsma PH
    PLoS One; 2016; 11(12):e0164485. PubMed ID: 27935941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Minor bleeds alert for subsequent major bleeding in patients using vitamin K antagonists.
    Veeger NJ; Piersma-Wichers M; Meijer K; Hillege HL
    Br J Haematol; 2011 May; 153(4):508-14. PubMed ID: 21418182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation.
    Roldán V; Marín F; Manzano-Fernández S; Gallego P; Vílchez JA; Valdés M; Vicente V; Lip GY
    J Am Coll Cardiol; 2013 Dec; 62(23):2199-204. PubMed ID: 24055744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bleeding predictors in patients following venous thromboembolism treated with vitamin K antagonists: Association with increased number of single nucleotide polymorphisms.
    Bryk AH; Wypasek E; Plens K; Awsiuk M; Undas A
    Vascul Pharmacol; 2018 Jul; 106():22-27. PubMed ID: 29432897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased risk of major bleeding after a minor bleed during treatment with vitamin K antagonists is determined by fixed common risk factors.
    van Rein N; le Cessie S; van Vliet IP; Reitsma PH; van der Meer FJ; Lijfering WM; Cannegieter SC
    J Thromb Haemost; 2016 May; 14(5):948-52. PubMed ID: 26988994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Choice of New Oral Anticoagulant Agents Versus Vitamin K Antagonists in Atrial Fibrillation: FANTASIIA Study.
    Moreno-Arribas J; Bertomeu-González V; Anguita-Sanchez M; Cequier Á; Muñiz J; Castillo J; Sanchis J; Roldán I; Marín F; Bertomeu-Martínez V;
    J Cardiovasc Pharmacol Ther; 2016 Mar; 21(2):150-6. PubMed ID: 26229096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship of the SAMe-TT₂R₂ score to poor-quality anticoagulation, stroke, clinically relevant bleeding, and mortality in patients with atrial fibrillation.
    Lip GYH; Haguenoer K; Saint-Etienne C; Fauchier L
    Chest; 2014 Sep; 146(3):719-726. PubMed ID: 24722973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant: a nationwide cohort study.
    Lamberts M; Gislason GH; Lip GY; Lassen JF; Olesen JB; Mikkelsen AP; Sørensen R; Køber L; Torp-Pedersen C; Hansen ML
    Circulation; 2014 Apr; 129(15):1577-85. PubMed ID: 24470482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparing thrombin generation in patients with hemophilia A and patients on vitamin K antagonists.
    de Koning MLY; Fischer K; de Laat B; Huisman A; Ninivaggi M; Schutgens REG
    J Thromb Haemost; 2017 May; 15(5):868-875. PubMed ID: 28296129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment with vitamin K antagonists: frequency of indications and appropriateness of continuation.
    van Der Heijden JF; Remkes MG; Büller HR; Vermeulen M
    Pathophysiol Haemost Thromb; 2002; 32(3):111-4. PubMed ID: 12372923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimization of vitamin K antagonist drug dose finding by replacement of the international normalized ratio by a bidirectional factor: validation of a new algorithm.
    Beinema MJ; van der Meer FJ; Brouwers JR; Rosendaal FR
    J Thromb Haemost; 2016 Mar; 14(3):479-84. PubMed ID: 26712475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selection, management, and outcome of vitamin K antagonist-treated patients with atrial fibrillation not switched to novel oral anticoagulants. Results from the Dresden NOAC registry.
    Michalski F; Tittl L; Werth S; Hänsel U; Pannach S; Sahin K; Weiss N; Beyer-Westendorf J
    Thromb Haemost; 2015 Nov; 114(5):1076-84. PubMed ID: 25994496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stroke and major bleeding risk in elderly patients aged ≥75 years with atrial fibrillation: the Loire Valley atrial fibrillation project.
    Lip GY; Clementy N; Pericart L; Banerjee A; Fauchier L
    Stroke; 2015 Jan; 46(1):143-50. PubMed ID: 25424474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteristics and quality of oral anticoagulation treatment in pediatric patients in the Netherlands based on the CAPS cohort.
    Maagdenberg H; Bierings MB; van Ommen CH; van der Meer FJM; Appel IM; Tamminga RYJ; de Boer A; Maitland-van der Zee AH
    J Thromb Haemost; 2018 Jan; 16(1):116-124. PubMed ID: 29108090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term quality of VKA treatment and clinical outcome after extreme overanticoagulation in 14,777 AF and VTE patients.
    Kooistra HA; Veeger NJ; Khorsand N; Kluin-Nelemans HC; Meijer K; Piersma-Wichers M
    Thromb Haemost; 2015 Apr; 113(4):881-90. PubMed ID: 25518854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness and safety of oral anticoagulation with non-vitamin K antagonists compared to well-managed vitamin K antagonists in naïve patients with non-valvular atrial fibrillation: Propensity score matched cohort study.
    Denas G; Gennaro N; Ferroni E; Fedeli U; Saugo M; Zoppellaro G; Padayattil Jose S; Costa G; Corti MC; Andretta M; Pengo V
    Int J Cardiol; 2017 Dec; 249():198-203. PubMed ID: 28935464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Independent predictors of poor vitamin K antagonist control in venous thromboembolism patients. Data from the EINSTEIN-DVT and PE studies.
    Kooistra HA; Gebel M; Sahin K; Lensing AW; Meijer K
    Thromb Haemost; 2015 Nov; 114(6):1136-43. PubMed ID: 26224199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bleeding risk in very old patients on vitamin K antagonist treatment: results of a prospective collaborative study on elderly patients followed by Italian Centres for Anticoagulation.
    Poli D; Antonucci E; Testa S; Tosetto A; Ageno W; Palareti G;
    Circulation; 2011 Aug; 124(7):824-9. PubMed ID: 21810658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quality of Vitamin K Antagonist Control and 1-Year Outcomes in Patients with Atrial Fibrillation: A Global Perspective from the GARFIELD-AF Registry.
    Haas S; Ten Cate H; Accetta G; Angchaisuksiri P; Bassand JP; Camm AJ; Corbalan R; Darius H; Fitzmaurice DA; Goldhaber SZ; Goto S; Jacobson B; Kayani G; Mantovani LG; Misselwitz F; Pieper K; Schellong SM; Stepinska J; Turpie AG; van Eickels M; Kakkar AK;
    PLoS One; 2016; 11(10):e0164076. PubMed ID: 27792741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
    Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M
    Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.